Stem Cell Res Ther. 2013;4(6):144. doi: 10.1186/scrt355.
Multiple myeloma is a common hematological malignancy that leads to the occurrence of bone lesions. The combination of traditional cytotoxic and novel agents is usually taken to treat multiple myeloma-related bone diseases. However, the curative effect is not very satisfactory. Stem cell-based therapy has been recently introduced and investigated, which represents a new frontier in the treatment of multiple myeloma. In a recent interesting study, Dr Atsuta and colleagues provide a new insight into the effects of mesenchymal stem cells on multiple myeloma via Fas/Fas ligand pathway, which rekindles the fire of hope for those patients suffering from multiple myeloma.
多发性骨髓瘤是一种常见的血液系统恶性肿瘤，可导致骨病变的发生。传统细胞毒性药物与新型药物联合应用通常用于治疗多发性骨髓瘤相关的骨疾病。然而，疗效并不十分满意。基于干细胞的治疗方法最近已经被引入并进行了研究，这代表了多发性骨髓瘤治疗的一个新领域。在最近一项有趣的研究中，Atsuta 博士及其同事通过 Fas/Fas 配体通路提供了关于间充质干细胞对多发性骨髓瘤影响的新见解，这为那些患有多发性骨髓瘤的患者重新燃起了希望。
